Loading…
MolluscumRx, Inc. was cited for marketing unapproved new drugs—"MolluscumRx" and "MolluscumRx Soap"—without FDA approval, in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act. The company promoted these products through its website and social media channels (Facebook, Twitter, and YouTube) as treatments for molluscum contagiosum, a viral skin infection that requires professional medical evaluation to rule out more serious conditions. The FDA was particularly concerned that these products were being marketed for use in children and could discourage consumers from seeking proper medical diagnosis and treatment.